BR112015014334A2 - método de tratamento usando o lactobacillus fermentum me-3 - Google Patents

método de tratamento usando o lactobacillus fermentum me-3

Info

Publication number
BR112015014334A2
BR112015014334A2 BR112015014334A BR112015014334A BR112015014334A2 BR 112015014334 A2 BR112015014334 A2 BR 112015014334A2 BR 112015014334 A BR112015014334 A BR 112015014334A BR 112015014334 A BR112015014334 A BR 112015014334A BR 112015014334 A2 BR112015014334 A2 BR 112015014334A2
Authority
BR
Brazil
Prior art keywords
lactobacillus fermentum
level
treatment
diabetes
decreasing
Prior art date
Application number
BR112015014334A
Other languages
English (en)
Inventor
Smidt Imbi
Zilmer Kersti
Mikelsaar Marika
Zilmer Mihkel
Hütt Pirje
Kullisaar Tiiu
Original Assignee
Univ Tartu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tartu filed Critical Univ Tartu
Publication of BR112015014334A2 publication Critical patent/BR112015014334A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G1/00—Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
    • A23G1/30—Cocoa products, e.g. chocolate; Substitutes therefor
    • A23G1/32—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds
    • A23G1/42—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • A23G1/423—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/143—Fermentum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dairy Products (AREA)
  • Confectionery (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

resumo resumo da patente de invenã§ã£o para: mã‰todo de tratamento usando o lactobacillus fermentum me-3 a invenã§ã£o fornece uma composiã§ã£o que compreende a cepa de lactobacillus fermentum me-3 dsm 14241 para uso na prevenã§ã£o, alã­vio dos sintomas ou tratamento, sozinha ou como um componente adjuvante, de um distãºrbio relacionado a uma sã­ndrome metabã³lica selecionado dentre prã©-diabetes, diabetes tipo 2 e doenã§a cardiovascular. o efeito pode ser alcanã§ado por, simultaneamente: diminuir o nã­vel de hemoglobina glicada hba1c, diminuir ou prevenir a inflamaã§ã£o de baixo grau a nã­vel celular e aumentar o nã­vel de adiponectina.
BR112015014334A 2012-12-24 2013-12-20 método de tratamento usando o lactobacillus fermentum me-3 BR112015014334A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1223370.6A GB201223370D0 (en) 2012-12-24 2012-12-24 Method of treatment using lactobacillus fermentum ME-3
PCT/IB2013/061216 WO2014102692A1 (en) 2012-12-24 2013-12-20 Method of treatment using lactobacillus fermentum me-3

Publications (1)

Publication Number Publication Date
BR112015014334A2 true BR112015014334A2 (pt) 2017-07-11

Family

ID=47682578

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015014334A BR112015014334A2 (pt) 2012-12-24 2013-12-20 método de tratamento usando o lactobacillus fermentum me-3

Country Status (17)

Country Link
US (1) US9974817B2 (pt)
EP (1) EP2943210B8 (pt)
JP (1) JP6484561B2 (pt)
AU (1) AU2013368969B2 (pt)
BR (1) BR112015014334A2 (pt)
CA (1) CA2896278C (pt)
DK (1) DK2943210T3 (pt)
ES (1) ES2649969T3 (pt)
GB (1) GB201223370D0 (pt)
HK (1) HK1216141A1 (pt)
LT (1) LT2943210T (pt)
MX (1) MX2015008298A (pt)
PH (1) PH12015501425A1 (pt)
PL (1) PL2943210T3 (pt)
RU (1) RU2015130679A (pt)
SG (1) SG11201504787VA (pt)
WO (1) WO2014102692A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3551202B1 (en) * 2016-12-06 2024-01-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
US11434468B2 (en) * 2017-01-13 2022-09-06 Bened Biomedical Co., Ltd. Lactic acid bacteria and its applications
KR101980527B1 (ko) * 2018-03-26 2019-05-21 주식회사 지놈앤컴퍼니 신규한 락토바실러스 퍼멘텀 lm1016 균주, 및 이를 포함하는 심혈관질환 예방 또는 치료용 조성물
WO2020045972A1 (ko) * 2018-08-31 2020-03-05 주식회사 메디오젠 항비만 활성을 갖는 인체 유래 락토바실러스 퍼멘툼 엠지4231 또는 락토바실러스 퍼멘툼 엠지4244 균주 및 이를 포함하는 조성물
KR101937758B1 (ko) * 2018-09-05 2019-01-11 마이크로바이오주식회사 락토바실러스 퍼멘텀 ubc-u32, 및 이의 퇴행성 뇌질환 예방 및 치료 용도
US20230012950A1 (en) * 2019-12-31 2023-01-19 Gi Biome Lactobacillus fermentum strain, and composition for preventing or treating metabolic diseases containing same
EP4086335A4 (en) * 2019-12-31 2023-10-11 Gi Biome LACTOBACILLUS FERMENTUM STRAIN, AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF METABOLIC DISEASES, INCLUDING THE SAME
CN115990124A (zh) * 2021-10-19 2023-04-21 百岳特生物技术（上海）有限公司 黄金百香果发酵物用于改善肌肤状态及抗光老化的用途
CN116210766A (zh) * 2022-11-03 2023-06-06 南京农业大学 一种提高酸奶黏度和益生活性的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1277953B1 (it) 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
AUPR101600A0 (en) 2000-10-25 2000-11-16 Atheromastat Pty Ltd Compositions and methods for diagnosis and treatment of cardiovascular disorders
EE04580B1 (et) 2001-06-29 2006-02-15 Tartu �likool Mikroorganismi tüvi Lactobacillus fermentum ME-3 kui antimikroobne ja antioksüdantne probiootikum
US6942857B2 (en) * 2002-08-09 2005-09-13 Bioneer Corporation Microorganisms for preventing and/or treating obesity or diabetes mellitus
DK2262514T3 (da) 2008-03-07 2020-02-10 Savencia Sa Midler til at fremme udskillelse og/eller undertrykke reduktion af adiponektin

Also Published As

Publication number Publication date
SG11201504787VA (en) 2015-07-30
US20150343003A1 (en) 2015-12-03
EP2943210B8 (en) 2018-01-10
RU2015130679A (ru) 2017-01-26
HK1216141A1 (zh) 2016-10-21
DK2943210T3 (en) 2018-01-02
EP2943210B1 (en) 2017-10-04
JP6484561B2 (ja) 2019-03-13
CA2896278A1 (en) 2014-07-03
EP2943210A1 (en) 2015-11-18
US9974817B2 (en) 2018-05-22
GB201223370D0 (en) 2013-02-06
LT2943210T (lt) 2017-12-11
CA2896278C (en) 2018-09-04
MX2015008298A (es) 2016-06-06
ES2649969T3 (es) 2018-01-16
PL2943210T3 (pl) 2018-02-28
AU2013368969B2 (en) 2018-06-14
JP2016511742A (ja) 2016-04-21
AU2013368969A1 (en) 2015-07-09
WO2014102692A1 (en) 2014-07-03
PH12015501425A1 (en) 2015-09-14

Similar Documents

Publication Publication Date Title
BR112015014334A2 (pt) método de tratamento usando o lactobacillus fermentum me-3
BR112012011478A2 (pt) composições fosfolipídicas terapêuticas concentradas.
EA201001698A1 (ru) Инсулиновые композиции сверхбыстрого действия
PH12018501969A1 (en) Pharmaceutical composition comprising empagliflozin and uses thereof
BR112015025256A2 (pt) cepas probióticas para uso no tratamento ou prevenção da osteoporose
BR112015007985A2 (pt) compostos do carboidrato galactose denteada para o tratamento de nefropatia diabética e distúrbios associados
BR112018013227A2 (pt) ?composições farmacêuticas ou kit para o uso, métodos para tratar câncer em um mamífero e uso de uma composição?
CL2014000801A1 (es) Variante de factor 21 de crecimiento de fibroblasto humano (fgf21); composicion farmaceutica que lo comprende; y su uso para tratar diabetes tipo 2, obesidad, dislipidemia, sindrome metabolico o cualquier combinacion de los mismos.
CL2012003226A1 (es) Compuestos derivados de 5-fluoro-1h-pirazolopiridina ; procedimiento de preparacion de estos; composicion framaceutica que los comprende; y su uso en el tratamiento de enfermedades cardiovasculares, sexuales y metabolicas.
CL2008002916A1 (es) Compuestos derivados de triazolopiridina, inhibidores 11-beta-hidroxiesteroide deshidrogenasa tipo i; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion de la diabetes, dislipidemia, obesidad, entre otros.
PH12015502275A1 (en) Therapuetic uses of empagliflozin
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
BR112014010275A2 (pt) formulações para tratamento de diabetes
UA96076C2 (en) Use of trans-clomiphene
WO2012072713A3 (en) Lysine demethylase inhibitors such as cyclylcyclopropanamine derivatives for use in the treatment of diseases and disorders associated with flaviviridae
BR112013010021A2 (pt) combinações farmacêuticas para o tratamento de distúrbios metabólicos.
BR112015001847A8 (pt) Composições e tratamento para doenças e distúrbios nos olhos
NO20083877L (no) Sammensetninger og fremgangsmater for behandling av immunoinflammatoriske forstyrrelser
BR112012031103A2 (pt) método para tratar um paciente sofrendo de um distúrbio metabólico, método para tratar pelo menos um desarranjo não-metabólico em um paciente, método para tratar pelo menos em desarranjo metabólico e pelo menos em desarranjo não-metabólico em um paciente, método para tratar pelo menos uma doença vascular em um paciente e composição farmacêutica efetiva para tratar a síndrome metabólica, diabetes tipo 2, obesidade, ou pré-diabetes
BRPI0813456A2 (pt) Composto, uso do mesmo, composição farmacêutica, e, métodos para tratar um mamífero sofrendo de um distúrbio e de uma doença
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
MX2009008166A (es) Metodo para disminuir la inflamacion y estres en un mamifero usando antimetabolitos de glucosa, aguacate o extractos de aguacate.
CL2009000309A1 (es) Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2.
BR112014024220A2 (pt) genes que codificam celulase
BR112014030534A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de doenças associadas com óxido nítrico sintase induzível elevada

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.